Electrophoretic Mobility Shift Assay
"Electrophoretic Mobility Shift Assay" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An electrophoretic technique for assaying the binding of one compound to another. Typically one compound is labeled to follow its mobility during electrophoresis. If the labeled compound is bound by the other compound, then the mobility of the labeled compound through the electrophoretic medium will be retarded.
| Descriptor ID |
D024202
|
| MeSH Number(s) |
E05.196.401.500
|
| Concept/Terms |
Electrophoretic Mobility Shift Assay- Electrophoretic Mobility Shift Assay
- EMSA Electrophoretic Technique
- EMSA Electrophoretic Techniques
- Electrophoretic Technique, EMSA
- Electrophoretic Techniques, EMSA
- Technique, EMSA Electrophoretic
- Techniques, EMSA Electrophoretic
- Band Shift Mobility Assay
- Mobility Shift Assay
- Assay, Mobility Shift
- Assays, Mobility Shift
- Mobility Shift Assays
- Bandshift Mobility Assay
- Assay, Bandshift Mobility
- Assays, Bandshift Mobility
- Bandshift Mobility Assays
- Mobility Assay, Bandshift
- Mobility Assays, Bandshift
Supershift Mobility Assay- Supershift Mobility Assay
- Assay, Supershift Mobility
- Assays, Supershift Mobility
- Mobility Assay, Supershift
- Mobility Assays, Supershift
- Supershift Mobility Assays
Gel Shift Analysis- Gel Shift Analysis
- Analyses, Gel Shift
- Analysis, Gel Shift
- Gel Shift Analyses
- Gelshift Analysis
- Gel Retardation Assay
- Assay, Gel Retardation
- Assays, Gel Retardation
- Gel Retardation Assays
|
Below are MeSH descriptors whose meaning is more general than "Electrophoretic Mobility Shift Assay".
Below are MeSH descriptors whose meaning is more specific than "Electrophoretic Mobility Shift Assay".
This graph shows the total number of publications written about "Electrophoretic Mobility Shift Assay" by people in this website by year, and whether "Electrophoretic Mobility Shift Assay" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 22 | 22 |
| 2003 | 1 | 19 | 20 |
| 2004 | 0 | 24 | 24 |
| 2005 | 0 | 21 | 21 |
| 2006 | 1 | 17 | 18 |
| 2007 | 0 | 21 | 21 |
| 2008 | 0 | 29 | 29 |
| 2009 | 0 | 20 | 20 |
| 2010 | 0 | 25 | 25 |
| 2011 | 0 | 23 | 23 |
| 2012 | 0 | 18 | 18 |
| 2013 | 1 | 22 | 23 |
| 2014 | 1 | 9 | 10 |
| 2015 | 0 | 6 | 6 |
| 2016 | 1 | 5 | 6 |
| 2017 | 0 | 3 | 3 |
| 2019 | 0 | 2 | 2 |
| 2020 | 1 | 1 | 2 |
Below are the most recent publications written about "Electrophoretic Mobility Shift Assay" by people in Profiles.
-
The role of cysteines in the structure and function of OGG1. J Biol Chem. 2021 Jan-Jun; 296:100093.
-
NF90 modulates processing of a subset of human pri-miRNAs. Nucleic Acids Res. 2020 07 09; 48(12):6874-6888.
-
Acyl-PEGyl Exchange Gel Shift Assay for Quantitative Determination of Palmitoylation of Brain Membrane Proteins. J Vis Exp. 2020 03 29; (157).
-
Infliximab and Adalimumab Concentrations May Vary Between the Enzyme-Linked Immunosorbent Assay and the Homogeneous Mobility Shift Assay in Patients With Inflammatory Bowel Disease: A Prospective Cross-Sectional Observational Study. Inflamm Bowel Dis. 2019 10 18; 25(11):e143-e145.
-
Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel Disease. J Crohns Colitis. 2019 Aug 14; 13(8):963-969.
-
AtrR Is an Essential Determinant of Azole Resistance in Aspergillus fumigatus. mBio. 2019 03 12; 10(2).
-
Cryo-EM Structure of Human Dicer and Its Complexes with a Pre-miRNA Substrate. Cell. 2018 05 17; 173(5):1191-1203.e12.
-
Nine Novel PAX9 Mutations and a Distinct Tooth Agenesis Genotype-Phenotype. J Dent Res. 2018 02; 97(2):155-162.
-
The Effect of RNA Secondary Structure on the Self-Assembly of Viral Capsids. Biophys J. 2017 Jul 25; 113(2):339-347.
-
A haplotype variant of the human chromogranin A gene (CHGA) promoter increases CHGA expression and the risk for cardiometabolic disorders. J Biol Chem. 2017 08 25; 292(34):13970-13985.